Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EBT: 2014-2024

Historic EBT for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$77.1 million.

  • Cartesian Therapeutics' EBT fell 30.10% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 59.92%. This contributed to the annual value of -$77.1 million for FY2024, which is 67.69% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported EBT of -$77.1 million as of FY2024, which was up 67.69% from -$238.7 million recorded in FY2023.
  • Over the past 5 years, Cartesian Therapeutics' EBT peaked at $34.8 million during FY2022, and registered a low of -$238.7 million during FY2023.
  • Moreover, its 3-year median value for EBT was -$77.1 million (2024), whereas its average is -$93.7 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' EBT spiked by 457.68% in 2022, and later crashed by 786.54% in 2023.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' EBT stood at -$68.9 million in 2020, then surged by 85.89% to -$9.7 million in 2021, then spiked by 457.68% to $34.8 million in 2022, then crashed by 786.54% to -$238.7 million in 2023, then surged by 67.69% to -$77.1 million in 2024.